NKTX Nkarta

Nkarta to Participate at Upcoming Investor Conferences

Nkarta to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:

Cowen 5th Annual IO Next Summit

November 15, 2021

11:15 a.m. ET - fireside chat presentation

Stifel 2021 Virtual Healthcare Conference

November 17, 2021

2:00 p.m. ET – fireside chat presentation

Evercore ISI 4th Annual HealthCONx Conference

December 1, 2021

4:20 p.m. ET – fireside chat presentation

A simultaneous webcast of the presentations will be available on the Investors section of Nkarta’s website, , and a replay will be archived on the website for approximately four weeks.

About Nkarta

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at .

Nkarta Media/Investor Contact:

Greg Mann

Nkarta, Inc.



EN
04/11/2021

Underlying

NKTXNkarta

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nkarta

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.31
STZ Constellation B...
OXY Occidental Petr... ... (+41)

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

STZ CONSTELLATION BRANDS INC. CLASS A
OXY OCCIDENTAL PETROLEUM CORPORATION
AMN AMN HEALTHCARE SERVICES INC.
PPC PILGRIM'S PRIDE CORPORATION
MDLZ MONDELEZ INTERNATIONAL INC. CLASS A
LAND GLADSTONE LAND CORP.
JCOM J2 GLOBAL INC.
JACK JACK IN THE BOX INC.
IPAR INTER PARFUMS INC.
INGR INGREDION INCORPORATED
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
EXPO EXPONENT INC.
EPC EDGEWELL PERSONAL CARE CO.
EMN EASTMAN CHEMICAL COMPANY
CLX CLOROX COMPANY
CE CELANESE CORPORATION
ACCO ACCO BRANDS CORPORATION
HRI HERC HOLDINGS INC.
OFLX OMEGA FLEX
WDFC WD-40 COMPANY
BOOM DMC GLOBAL INC
UAA UNDER ARMOUR INC. CLASS A
NHF NEXPOINT CREDIT STRATEGIES FUN
IOVA IOVANCE BIOTHERAPEUTICS INC
FNKO FUNKO CLASS A
SPB SPECTRUM BRANDS HOLDINGS INC.
AVNS AVANOS MEDICAL INC.
DOW DOW INC.
AMCR AMCOR PLC
ATEX ANTERIX INC
BJ BJ'S WHOLESALE CLUB HOLDINGS
NVAX NOVAVAX INC.
VIR VIR BIOTECHNOLOGY
ALT ALTIMMUNE INC
NKTX NKARTA
PTLO PORTILLOS INC
CHRD CHORD ENERGY CORPORATION
LIN LINDE PUBLIC LIMITED COMPANY
HUN GLOBAL X NATURAL GAS ETF
INR INFINITY NATURAL RESOURCES INC
MUSA MIDDLEFIELD US EQUITY DIV ET ETF UN
01/28/26 January 28, 2026 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta to Participate in Evercore Healthcare Conference

Nkarta to Participate in Evercore Healthcare Conference SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the Evercore 8th Annual Healthcare Conference on Thursday in Miami. Evercore 8th Annual Healthcare ConferenceDecember 4, 202510:50 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the of Nkarta’s website, and a replay will be archived on the web...

December 2, 2025 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta Reports Third Quarter 2025 Financial Results and Corporate High...

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights  Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide versus partial B-cell depletion in patients receiving only cyclophosphamideEnrollment streamlined across Ntrust-1 and Ntrust-2 under a combined independent Data Safety Monitoring Board (iDSMB) to guide dose escalation Initial data for NKX019 in multiple autoimmune indications expected to be presented at a medical conf...

November 10, 2025 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta to Participate in November Investor Conferences

Nkarta to Participate in November Investor Conferences SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences next month: Stifel 2025 Healthcare ConferenceNovember 12, 202510:40 a.m. ET – fireside chat TD Cowen’s Immunology & Inflammation SummitNovember 13, 20255 p.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s web...

October 30, 2025 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta Announces Poster Presentation at Upcoming American College of R...

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced it will be presenting a poster this Sunday in Chicago at the American College of Rheumatology (ACR) Convergence 2025 meeting. Nkarta will present clinical data showing that the company’s investigational therapy, NKX019, achieved robust pathogenic B-...

October 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch